CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.
- What Goes Into Restarting A Shelved Orphan Drug Candidate?
- A Much-Improved Approach For Understanding And Managing Safety Risks
- Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission
- CSV Assumes The AI System Sits Still — It Doesn't.
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
- Combination Cell Therapy's Clinical Success Hinges On Manufacturability
- Are Biopharma Companies Outsourcing Their Ability To Think?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1068302874-3d-cells-culture]( "3D Cell Culture Reveals Undetectable Drug Efficacy In Traditional Systems")
3D Cell Culture Reveals Undetectable Drug Efficacy In Traditional SystemsDrug discovery now targets cancer stem cells (CSCs) to achieve long-term tumor eradication, which moves beyond traditional chemotherapeutics. Discover an advanced screening platform that better predicts CSC inhibitor efficacy.
-
![GettyImages-1184711342-imaging-cancer-cells]( "Studying The Spatial Architecture Of Glioblastoma")
Studying The Spatial Architecture Of GlioblastomaExplore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).
-
![GettyImages-2150364155-hand-digital-documents-validation]( "Mid-Sized Pharma Optimizes Local Affiliate Safety Operations")
Mid-Sized Pharma Optimizes Local Affiliate Safety OperationsManaging local affiliate PV strains any team. See how a mid-sized biopharma standardized ICSR processing across 94 countries, improved compliance tracking, and achieved centralized oversight.
-
![GettyImages-2178790629 cell]( "Ex-Vivo T Cell Depletion In Allogeneic HSCT")
Ex-Vivo T Cell Depletion In Allogeneic HSCTExplore a flexible cell depletion strategy that selectively removes targeted immune cell populations while preserving beneficial subsets, supporting tailored graft engineering approaches.
-
![GettyImages-2148703252-DNA-helix-blue]( "Rapid And Sensitive Detection Of Replication-Competent Lentivirus (RCL)")
Rapid And Sensitive Detection Of Replication-Competent Lentivirus (RCL)See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
![90 Minutes On A Stopwatch GettyImages-2162646082]( "High-Throughput 90-Minute ELISA")
High-Throughput 90-Minute ELISADiscover how one solution can be utilized to measure Human IgG and human IFN gamma, which are key targets in pharmacokinetic studies and immunotherapeutic drug safety testing, in just 90 minutes.
-
![GettyImages-1327318287-spheres-cancer-cells-microscopic]( "Cell Culture Automation Of The 3D Cancer Spheroid Assay")
Cell Culture Automation Of The 3D Cancer Spheroid AssayDiscover how automated 3D cell culture methods enhance efficiency and consistency in high-throughput drug screening to accelerate the discovery of new anti-cancer therapies.
-
![GettyImages-1411964582-scientist-microscope-testing-food-quality]( "Negative Stain TEM For Viral Particle Characterization")
Negative Stain TEM For Viral Particle CharacterizationStandardized latex bead references combined with negative stain TEM provide precise viral particle characterization and consistent viral load quantification.
-
![cell engineering, cell programming-GettyImages-1429299555]( "Evaluating Clone Performance And Cell-Specific Productivity")
Evaluating Clone Performance And Cell-Specific ProductivitySee how continuous process monitoring and automated at-line analytics support confident CHO clone ranking, consistent cultivation, and scale-up by connecting pH, viable cell density, and more.
-
![GettyImages-1790778296-laboratory-research-sample-prep]( "Streamlining Analytical Release Testing With Faster, Smaller Workflows")
Streamlining Analytical Release Testing With Faster, Smaller WorkflowsReducing turnaround times and sample volumes in release testing can accelerate cell therapy manufacturing, preserve product yield, and improve patient outcomes.
NEWSLETTER ARCHIVE
- 08.21.26 -- Smarter Workflows For Cell & Gene Production
- 08.21.26 -- Rewriting The Playbook For Stargardt Disease With Shannon Boye, Ph.D.
- 08.20.26 -- Are Biopharma Companies Outsourcing Their Ability To Think?
- 08.19.26 -- Building A More Scalable Gene Therapy Program
- 08.19.26 -- Scaling Human-Relevant Science For Biologics Development
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
